阿泰生命科学
ATAI
0.00
0.00
0.00%
阿泰生命科学
US · ATAI
#2575 按市值排名
上市于 2021
0.00
0.00
0.00%
实时 - 追踪5344个代码 - 心跳于256秒前
· 2026-10-16 09:30
最新新闻
-
公司公告
ATAI Life Sciences | 4: Statement of changes in beneficial ownership of securities-10% Owner Apeiron Investment Group Ltd.SEC · 2025/3/25
-
H.C. Wainwright Maintains AtaiBeckley(ATAI.US) With Hold Rating, Maintains Target Price $7.5\u5e02\u573a\u8d44\u8baf · 2026/8/21
-
U.S. Stocks Move Sharply | Atai Life Sciences plc (ATAI.US) Surges Over 30% at Open Following Eli Lilly and Co's Acquisition Offer of Up to $3.8 BillionZhitong Finance · 2026/7/16
-
Deutsche Bank Downgrades AtaiBeckley(ATAI.US) to Hold Rating, Cuts Target Price to $8\u5e02\u573a\u8d44\u8baf · 2026/8/12
-
评级变动
H.C. Wainwright Downgrades AtaiBeckley(ATAI.US) to Hold Rating, Cuts Target Price to $7.5\u5e02\u573a\u8d44\u8baf · 2026/7/20
-
评级变动
A Quick Look at Today's Ratings for AtaiBeckley(ATAI.US), With a Forecast Between $7.5 to $8\u5e02\u573a\u8d44\u8baf · 2026/7/17
-
公司公告
ATAI Life Sciences | 4: Statement of changes in beneficial ownership of securities-10% Owner Apeiron Investment Group Ltd.SEC · 2025/10/3
-
公司公告
ATAI Life Sciences | 4: Statement of changes in beneficial ownership of securities-10% Owner Apeiron Investment Group Ltd.SEC · 2025/8/19
-
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)TipRanks · 2026/8/20
-
评级变动
Berenberg Bank Sticks to Their Buy Rating for Atai Beckley N.V. (ATAI)TipRanks · 2026/7/18
-
公司公告
AtaiBeckley: AtaiBeckley Inc. - Anticipated Cash Settlement Option Symbol: ATAIOCC · 2026/8/12
-
公司公告
AtaiBeckley: AtaiBeckley Inc. - Cash Settlement/Acceleration of Expirations Option Symbol: ATAIOCC · 2026/9/11
-
评级变动
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)TipRanks · 2026/8/12
-
评级变动
Maxim Group Maintains AtaiBeckley(ATAI.US) With Hold Rating\u5e02\u573a\u8d44\u8baf · 2026/7/18
-
评级变动
Berenberg Bank Downgrades AtaiBeckley(ATAI.US) to Hold Rating, Cuts Target Price to $7.45\u5e02\u573a\u8d44\u8baf · 2026/7/20
-
评级变动
Berenberg Bank Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $14\u5e02\u573a\u8d44\u8baf · 2026/7/18
-
评级变动
Oppenheimer Downgrades AtaiBeckley(ATAI.US) to Hold Rating\u5e02\u573a\u8d44\u8baf · 2026/8/18
-
评级变动
TD Cowen Downgrades AtaiBeckley(ATAI.US) to Hold Rating\u5e02\u573a\u8d44\u8baf · 2026/7/18
-
评级变动
Jefferies Maintains AtaiBeckley(ATAI.US) With Hold Rating, Maintains Target Price $7.5\u5e02\u573a\u8d44\u8baf · 2026/7/17
-
News On AtaiBeckley Inc. (ATAI) Now Under LLYDow Jones · 2026/9/12
新闻标题为自动聚合内容,未经我们团队独立核实或编辑。
报价时间 2026-10-16 09:30:00 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
阿泰生命科学 讨论区 0 条评论